



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Raúl J. Andrade**

Organisation/Company: University of Malaga

Country: Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
09/2009-12/2016	Johnson&Johnson	Rivaroxaban	anticoagulation (consultancy as an hepatotoxicity expert)
02/2011-04/2011	NicOx	Naproxinod	Osteoarthritis (consultancy as an hepatotoxicity expert)
06/2012-09/2013	Aegerion Pharmaceuticals (NASDQ:AEGR)	Lomitapide	HoFH (consultancy as an hepatotoxicity expert)
08/2011-02/2015	Janssen	Canigliflozin	Diabetes mellitus
05/2019-(current)	Obseva	Linzagolix	Uterine fibroids (consultancy as an hepatotoxicity expert)
12/2019-(current)	Novo-Nordisk	Semaglutide	NASH (consultancy as an hepatotoxicity expert)
02/2019-02/2019	Daichii-Sankyo	Pexidartinib	Tenosynovial giant cell tumours (consultancy as an hepatotoxicity expert)
04/2020-(current)	Mylan	Silimarin	NASH, DILI (Kol)
11/2020-(current)	ENYO	Vonfexor	NASH, HBV (consultancy as an hepatotoxicity expert)

Classified as public by the European Medicines Agency

2

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2011-03/2013	BMS	BMS-650032	hepatitis C
01/2011-03/2016	Janssen	Telaprevir	Hepatitis C
09/2011-09/2015	Gilead	Tenofovir	Hepatitis B
03/2008-05/2010	GSK	Eltrombopag	Hepatitis C
05/2010-12/2012	Bayer Healthcare	Sorafenib	Hepatocellular carcinoma
01/2012-01/2017	Bristol-Myers Squibb International Corporation	Peg-interferon alfa-2a, Ribavirine & BMS-790052	Hepatitis C crónica
04/2013-06/2014	Dr. Jose Luis Montero Álvarez	Sorafenib	Hepatocellular carcinoma
10/2012-02/2014	GILEAD SCIENCES	GS-7977 + ribavirine	Chronic VHC
10/2012-(current)	Bristol-Myers Squibb, S.A	Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)	Chronic Hepatis C
01/2013-06/2015	GENFIT	GFT505 80 mg and GFT505 120 mg	Esteatohepatitis no alcohólica (EHNA).
03/2013-06/2014	GILEAD SCIENCES Inc	Sofosbuvir/GS-5885 ± ribavirina	VHC genotype 1
02/2013-09/2014	Boehringer Ingelheim España S.A.	BI 207127	Chronic Hepatitis C (genotype 1)
10/2014-(current)	Ocera Therapeutics	OCR 002 (fenilacetato de ornitina)	Cirrhosis and hyperammonemia asociated with hepatic encephalopathy
02/2015-(current)	AbbVie deutschland Gmbh & Co K.G	ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) y ABT-333 con o sin ribavirina (RBV)	Hepatitis C (genotype 1)
12/2015-(current)	Gilead Sciences International Ltd	Tenofovir DF, Viread®	Chronic hepatitis B (HBC)

## 2.7 Grant / Funding to organisation /institution

Classified as public by the European Medicines Agency

DOI Form Version-number: 4

Company	Subject Matter
Boehringer Ingelheim (years 2009/2010)	Hepatotoxicity studies

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

Lecture fees previously from Janssen, MSD, Bayer Healthcare, BMS, Gilead, Gore.

Regarding Aegerion: This is a consultancy recently agreed and I have no information of this product yet. No meeting is planned before 10 September, payment only upon once services are provided.

Regarding J&J: Last meeting in (April 10 2012) to start assessing some specific post-marketing cases. No new cases have been assessed yet and no meeting is planned before 10 September, payment for the time devoted to assess cases.

Regarding Janssen: no meeting planned before 10 september, payment only upon once services are provided.

## 2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.

Classified as public by the European Medicines Agency

- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	RAUL J. ANDRADE BELLIDO
Date:	2022-09-19

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*